sub:assertion {
d:DB00748 dv:ddi-interactor-in dr:DB00748_DB00895 .
d:DB00895 dv:ddi-interactor-in dr:DB00748_DB00895 .
dr:DB00748_DB00895 dct:identifier "drugbank_resource:DB00748_DB00895" ;
dct:title "DDI between Carbinoxamine and Benzylpenicilloyl Polylysine - Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Treatment with systemic histamine H1 antagonists such as carbinoxamine should be suspended for benzylpenicilloyl-polylysine skin testing to minimize the potential for false negative results. Delay skin testing until the systemic effects of the antihistamine have dissipated. A histamine skin test may be used to assess residual antihistaminic effects."@en ;
a dv:Drug-Drug-Interaction ;
rdfs:label "DDI between Carbinoxamine and Benzylpenicilloyl Polylysine - Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Treatment with systemic histamine H1 antagonists such as carbinoxamine should be suspended for benzylpenicilloyl-polylysine skin testing to minimize the potential for false negative results. Delay skin testing until the systemic effects of the antihistamine have dissipated. A histamine skin test may be used to assess residual antihistaminic effects. [drugbank_resource:DB00748_DB00895]"@en .
}